# West Pharmaceutical Services, Inc. (WST) — Stock CV

West Pharmaceutical Services, Inc. is a $25.8B healthcare company. Revenue grew 12.4% over the last year, it keeps 17¢ of every dollar of sales as profit, and it holds more cash than debt. It trades at 47.7× earnings — around the middle of its own history.

> West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries.

## Identity

- **Ticker**: WST
- **Sector**: Healthcare
- **Industry**: Surgical & Medical Instruments & Apparatus
- **Headquarters**: EXTON, PA
- **Employees**: 10 800
- **Website**: https://www.westpharma.com
- **Market cap**: $25.8B
- **Last price**: $366.00
- **Financial profile**: Mixed

## Vitals (TTM)

- **Revenue**: $3.33B
- **Net income**: $565M
- **Free cash flow**: $437M
- **Net cash**: $589M
- **P/E**: 47.7
- **Revenue growth (YoY)**: 12.4%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 34 |
| Growth | 38 |
| Profitability | 80 |
| Health | 75 |
| Quality | 82 |
| Moat | 81 |

## Qualifications (beginner checklist) — 9 of 11 passed

- [x] Revenue growing — +12.4% YoY
- [x] Profitable — $565M TTM
- [ ] Profit growing — -4.2% YoY
- [x] Generates cash — $437M TTM
- [x] Debt under control — more cash than debt
- [x] Established company — $25.8B market cap
- [x] Not printing shares — -4.1% shares over ~5y
- [x] Proven track record — 10/10 profitable years
- [ ] Financially stable — health score 50/100
- [x] Pays a dividend — yield 0.23%
- [x] Valuation not extreme — P/E 47.7

## Experience (career milestones)

- **FY2021** — Best year on record: $662M net income
- **FY2017** — Became debt-free: cash now exceeds total debt
- **FY2016** — Profitable every year on record: 10 consecutive profitable years in our data
- **FY2016** — Revenue already above $1B: $1.51B in first reported year
- **FY2016** — Positive free cash flow every year since: 10-year streak
- **2005** — West acquired The Tech Group, Scottsdale, Ariz., and Medimop Medical Projects Ltd., Ra’anana, Israel

## Strengths

- Revenue growing 12.4% year over year
- Net cash position after subtracting debt from cash
- Interest covered 130.1× by operating earnings
- High returns on invested capital (ROIC 19.1%)
- Piotroski F-Score 7/9 — fundamentally strong checklist

## Watch-outs

- None stand out in the data.

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $2.83B | $662M | $331M |
| FY2022 | $2.89B | $586M | $439M |
| FY2023 | $2.95B | $593M | $415M |
| FY2024 | $2.89B | $493M | $276M |
| FY2025 | $3.07B | $494M | $469M |

---

Source: https://stockcv.com/WST — derived from company filings; may be delayed or incomplete. Information, not investment advice.